Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$772.7 million.

  • Century Therapeutics' Retained Earnings fell 354.75% to -$772.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$772.7 million, marking a year-over-year decrease of 354.75%. This contributed to the annual value of -$782.3 million for FY2024, which is 1930.03% down from last year.
  • Per Century Therapeutics' latest filing, its Retained Earnings stood at -$772.7 million for Q3 2025, which was down 354.75% from -$738.3 million recorded in Q2 2025.
  • Century Therapeutics' Retained Earnings' 5-year high stood at -$425.7 million during Q1 2022, with a 5-year trough of -$782.3 million in Q4 2024.
  • Its 4-year average for Retained Earnings is -$629.3 million, with a median of -$655.8 million in 2023.
  • As far as peak fluctuations go, Century Therapeutics' Retained Earnings tumbled by 2929.04% in 2023, and later tumbled by 320.9% in 2025.
  • Over the past 4 years, Century Therapeutics' Retained Earnings (Quarter) stood at -$519.1 million in 2022, then fell by 26.33% to -$655.8 million in 2023, then decreased by 19.3% to -$782.3 million in 2024, then rose by 1.23% to -$772.7 million in 2025.
  • Its last three reported values are -$772.7 million in Q3 2025, -$738.3 million for Q2 2025, and -$705.8 million during Q1 2025.